Targeting the TRIM25-AGO2-miR-148b-5p-ABCC1 axis overcomes chemoresistance in non-small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Acquired resistance to chemotherapy is a significant challenge in advanced non-small cell lung cancer (NSCLC).
• Understanding the molecular mechanisms of chemoresistance is critical for developing effective treatment strategies.

Purpose of the Study:

• To identify key molecular regulators driving tumor progression and chemoresistance in NSCLC.
• To elucidate the mechanistic pathway involved in TRIM25-mediated chemoresistance.
• To evaluate the therapeutic potential of targeting this pathway for NSCLC treatment.

Main Methods:

• Investigated the role of TRIM25 in NSCLC chemoresistance.
• Utilized biochemical assays to determine the interaction between TRIM25 and AGO2.
• Performed ubiquitination assays and proteasomal degradation studies.
• Assessed the impact of TRIM25 modulation on miR-148b-5p and ABCC1 expression.
• Evaluated the efficacy of miR-148b-5p mimics in preclinical NSCLC models.

Main Results:

• TRIM25 destabilizes AGO2 through polyubiquitination and proteasomal degradation.
• This process leads to the downregulation of tumor-suppressive miR-148b-5p.
• Downregulated miR-148b-5p results in the upregulation of ABCC1, promoting chemoresistance.
• Knockdown of TRIM25 restores AGO2 stability, reinstates miR-148b-5p, and suppresses ABCC1.
• Therapeutic delivery of miR-148b-5p mimics demonstrated significant anti-tumor activity and overcame chemoresistance in various NSCLC models.

Conclusions:

• The TRIM25-AGO2-miR-148b-5p-ABCC1 axis is a novel regulatory pathway in NSCLC chemoresistance.
• Targeting TRIM25 or delivering miR-148b-5p mimics represents a promising therapeutic strategy for overcoming chemoresistance in NSCLC.
• This study provides mechanistic insights and highlights translational potential for novel NSCLC therapies.